Frey NV, Gill S, Hexner EO, et al. - This study is done with patients suffering from relapsed or refractory chronic lymphocytic leukemia (CLL), to determine long-term results of anti-CD19 chimeric antigen receptor T (CART) cells in this patient population. Enrolled patients were 42 in total. Overall 38 patients were infused with anti-CD19 CART cells (CART-19). For the 32 evaluable patients, complete and overall responses were estimated to be 28% and 44%, respectively, at 4 weeks. As per findings, a likely greater effectiveness of a 5 × 10⁸ dose of CART-19 vs 5 × 10⁷ CART-19 at inducing CR without excessive toxicity was suggested in patients with advanced CLL. In patients with relapsed CLL, longer overall survival and progression-free survival were observed in relation to achievement of a CR post-CART-19 infusion, irrespective of cell dose.